
Peter LeWitt MD
Movement Disorder, Neurodegenerative, Dementia & Geriatrics
Physician
Join to View Full Profile
6777 W Maple RdWest Bloomfield, MI 48322
Phone+1 248-325-2452
Fax+1 248-325-3115
Dr. LeWitt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- National Institutes of HealthFellowship, 1980 - 1983
- Stanford Health Care1977 - 1980
- Brown UniversityM.Med.Sc., Biochemical Pharmacology, 1971 - 1975
- The Warren Alpert Medical School of Brown UniversityClass of 1975
Certifications & Licensure
- MI State Medical License 1983 - 2027
- MD State Medical License 1982 - 1984
- PA State Medical License 1976 - 1978
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease Start of enrollment: 2007 Oct 01
- Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease Start of enrollment: 2012 Apr 01
- Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Start of enrollment: 2012 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Getting an earful of stimulation: A novel means for neuromodulation of Parkinson disease.Peter A LeWitt
Parkinsonism & Related Disorders. 2024-04-01 - 3 citationsBuspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.Peter A LeWitt, Glenn T Stebbins, Kenneth Vielsted Christensen, Riswanto Tan, Anél Pretorius
Movement Disorders. 2024-03-01 - 1 citationsHidden Gems in the Neurological Literature of Progressive Supranuclear Palsy.Peter A LeWitt
Journal of Parkinson's Disease. 2024-01-01
Press Mentions
- Phase 1 Trial Set to Test First Live Biotherapeutics in Parkinson’sFebruary 23rd, 2022
- 4D Pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseFebruary 22nd, 2022
- HIMSS21 Day 3 Roundup: Sharecare Acquires CareLinx, Verizon Telehealth, SamsungAugust 11th, 2021
- Join now to see all
Professional Memberships
- Movement Disorder SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: